12 November 2012; AstraZeneca, one of the top worldwide pharmaceutical companies has to shelve off its early-stage clinical study allied to the obesity medication within a few weeks of the research initiation.
This cessation of the clinical study was forced to be called off following an apparent allergic complication in one of the enrolled 72 patients.
This is one of the main research studies that Palatin Technologies has approved in their 5 year old partnership with the AstraZeneca drug manufacturing company. Currently, the company plans to shift its focus on other clinical tie-ups and start working with them. AstraZeneca has been forced to write off an early-stage obesity drug.
This is the latest setback to the pharmaceutical company in a long term clinical drawbacks but the company has taken an initiate to kick start its pipeline projects with new zeal and enthusiasm.
Dr Carl Spana, CEO of Palatin said that the drug AZD2820 is one of the major R&D collaboration of the company with AstraZeneca; but they do have various other coalition compounds that are in their initial stage of clinical testing. AstraZeneca and partner Palatin Technologies have halted a Phase I trial of an investigational obesity drug after a participant fell ill.
He also added that AstraZeneca will remain committed to them about the clinical advancements in the obesity treatment approach of the collaboration compounds.
The drug code named as AZD2820, functions as a partial agonist of melanocortin-4 receptor peptide to carry out the anti-obesity effect.
The deal was signed in the year 2007 but the unexpected side effect gave a big blow to the clinical targets of the company although, the patients experiencing the allergic manifestation recovered from the condition completely.
Jack is a Medical Student and a freelancer who is specialized in writing. He is associate with many Pharmacies for whom he writes articles based on generic drugs and general health related issues.